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Metabolomic profiling of obese versus lean humans
reveals a branched-chain amino acid (BCAA)-related
metabolite signature that is suggestive of increased
catabolism of BCAA and correlatedwith insulin resis-
tance. To test its impact on metabolic homeostasis,
we fed rats on high-fat (HF), HF with supplemented
BCAA (HF/BCAA), or standard chow (SC) diets.
Despite having reduced food intake and a low rate
of weight gain equivalent to the SC group, HF/BCAA
rats were as insulin resistant as HF rats. Pair-feeding
of HF diet to match the HF/BCAA animals or BCAA
addition to SC diet did not cause insulin resistance.
Insulin resistance induced by HF/BCAA feeding was
accompanied by chronic phosphorylation of mTOR,
JNK, and IRS1Ser307 and by accumulation of multiple
acylcarnitines in muscle, and it was reversed by the
mTOR inhibitor, rapamycin. Our findings show that
in the context of a dietary pattern that includes high
fat consumption, BCAA contributes to development
of obesity-associated insulin resistance.
INTRODUCTION
Obesity has reached epidemic proportions in many countries
around the world and is strongly linked to a number of chronic
diseases, including diabetes, hypertension, and cardiovascular
disease (Hedley et al., 2004; Sowers, 2003). Whereas many
comparisons of obese and lean subjects exist in the literature,
these are often focused on one or a small group of experimental
variables. Here, we sought to apply comprehensive metabolic
profiling tools togainabroader understandingofmetabolic, endo-
crine, inflammatory, and physiologic differences between obese
and lean subjects. Included were measurements of 19 hormonesofenergybalanceand fuel homeostasis; 4pro-andanti-inflamma-
tory cytokines; physiological variables such as insulin sensitivity,
body composition, and resting metabolic rate; 10 metabolites
assayed by conventional enzyme assays; and as a novel feature,
98 intermediary metabolites in 6 chemical groups measured by
targeted mass spectrometry (MS) (Haqq et al., 2005).
This comprehensive metabolic profiling was performed on
74 obese (median BMI of 36.6 kg/m2) and 67 lean (median BMI
of 23.2 kg/m2) subjects. We selected ‘‘healthy’’ obese subjects,
freeofdiabetesor other serious illness.Not surprisingly,we found
the obese participants to be more insulin resistant, on average,
than the lean controls. We also found a distinctive metabolic
‘‘signature’’ related to branched-chain amino acid (BCAA) catab-
olism in obese subjects. Animal studies based on these findings
demonstrate that supplementation of a high-fat (HF) diet with
BCAA (HF/BCAA) reduces food intake and body weight, but
causes the animals to be insulin resistant equally to heavier
animals fed on a nonsupplemented HF diet. Importantly, animals
fed on HF diet at a rate matched to that of the HF/BCAA-fed
animals do not become insulin resistant, and the HF/BCAA-
induced insulin resistance is selectively reversed by the mTOR
inhibitor rapamycin. From these findings, we propose a pathway
bywhich dysregulatedBCAAmetabolismmakes an independent
contribution to development of insulin resistance and glucose
intolerance, ultimately leading to type 2 diabetes.
RESULTS
Demographics and Clinical Characteristics
Seventy-three obese and sixty-seven lean subjects underwent
baseline evaluation. The obese subjects were comprised of
70% women and 41% African Americans, whereas the lean
subjects were 57%women and 45%African Americans. Median
age of the obese subjects was 52 years, and their median BMI
was 36.6 kg/m2, compared to 50 years and 23.2 kg/m2 for the
lean controls. Additional demographic and clinical data are
provided in Table 1.Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 311
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Obese Lean P value
Baseline characteristics n = 74 n = 67
Age (years) 52.0 (46.0, 60.0) 50.0 (38.0, 60.0) 0.2391
African-American 30 (40.5%) 30 (44.8%) 0.6115
Female 52 (70.3%) 38 (56.72%) 0.0944
BMI (kg/m2) 36.6 (32.7, 40.7) 23.2 (21.8, 23.8) <0.0001
Lean, BMI < 25 kg/m2 0 (0.0%) 67 (100.0%) <0.0001
Obese, stage I (30–34.9 kg/m2) 28 (37.8%) 0 (0.0%)
Obese, stage II (35–39.9 kg/m2) 24 (32.4%) 0 (0.0%)
Obese, stage III (>40 kg/m2) 22 (29.7%) 0 (0.0%)
Waist circumference (cm)a 112.6 (103.9, 117.7) 84.1 (78.0, 88.7) <0.0001
Taking lipid medication 29 (39.2%) 9 (13.4%) 0.0006
Taking blood pressure medication 50 (67.6%) 16 (23.9%) <0.0001
Dietary intake (% of kcal) n = 66 n = 66
Fat 42.2 (37.1, 46.8) 35.7 (31.1, 39.7) <0.0001
Carbohydrate 43.4 (37.6, 48.7) 50.0 (41.9, 55.0) 0.0005
Protein 15.5 (13.5, 18.2) 14.3 (13.0, 16.9) 0.0719
Physical activity (METs)b 1431 (459, 3510) 2126 (1386, 3816) 0.0957
Physiologic measuresc
Body composition
Fat mass (kg) 36.45 (31.92, 43.38) 18.65 (13.66, 21.38) <0.0001
Lean mass (kg) 55.09 (49.60, 68.43) 45.45 (41.28, 58.20) <0.0001
Subcutaneous fat (area) 37903.00 (34958.00, 46235.00) 16176.00 (12186.00, 22042.00) <0.0001
Visceral fat (area) 20971.00 (14004.00, 26325.00) 6712.50 (4068.50, 9865.00) <0.0001
Resting metabolic rate
REE/LBM (ratio) 28.02 (25.98, 30.41) 29.32 (26.84, 32.06) 0.027
RER/RQ (ratio) 0.85 (0.79, 0.90) 0.81 (0.78, 0.84) 0.0038
Insulin resistance
HOMA 5.73 (3.88, 8.29) 2.51 (2.01, 3.32) <0.0001
Si 2.12 (1.27, 2.99) 4.44 (3.66, 6.30) <0.0001
AIRG 599.00 (329.00, 924.00) 398.00 (223.00, 569.00) 0.0491
All results presented as medians (25th, 75th percentile) or n (percent). n for subcutaneous fat = 41 and 60 and for visceral fat = 47 and 60 for obese and
lean, respectively. n for REE/LBM= 45 obese and 62 for lean; n for RER = 53 and 62 for obese and lean. n for HOMA= 74 for obese and 67 for lean. n for
Si = 26 for obese and 25 for lean and AIRG = 26 for both obese and lean, respectively. n for fat and lean mass = 48 for obese and 64 for lean.
a n for measurement of waist circumference = 68 for obese and 62 for lean.
b n for measurement of physical activity = 47 for obese and 59 for lean.
c n varies due to variations in completion of data collection.Based on self-administered Block Food Frequency Question-
naire (Harlan and Block, 1990), obese subjects had a higher
dietary intake of fat (p < 0.0001), a lower intake of carbohydrate
(p = 0.0005), and a trend toward an increase in protein consump-
tion (p = 0.072). Physical activity measured by the International
Physical ActivityQuestionnaire trended lower in obesecompared
to lean subjects (p = 0.0957).
Physiologic Measures
Obese subjects had twice as much total fat mass as lean
controls, but only a 17% increase in lean mass (Table 1). The
higher total fat mass in obese subjects was accompanied by
a 2.3-fold increase in subcutaneous fat mass and a 3.1-fold
increase in visceral fat mass (p < 0.0001 in both cases). Respira-
tory exchange rate (RER), also known as respiratory quotient312 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.(RQ), was significantly higher in obese subjects (p = 0.0038).
Thus, obese subjects appear to have a preference for oxidation
of nonlipid fuels (glucose and amino acids) compared to lean
controls (as indicated by the higher RQ), even though they have
substantially larger total, subcutaneous, and visceral fat depots.
Obese subjects were less insulin sensitive than the lean
controls, by two independent criteria (Table 1). First, the homeo-
stasis model assessment (HOMA) index was 2.3-fold higher in
obese subjects than in lean controls (p < 0.0001). Second, in
a subset of 26 obese and 26 lean subjects who underwent intra-
venous glucose tolerance testing (IVGTT), the insulin sensitivity
index, Si, was 2.1-fold higher in lean subjects (p < 0.001). The
obese subjects who underwent IVGTT also showed a trend
towardhigher acute insulin response toglucose (AIRG;p=0.049),
consistent with obesity-related insulin resistance.
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Among a total of 19 hormones of energy balance and metabolic
regulation measured in this study, only 5 were not significantly
different in obese versus lean subjects: amylin, glucagon-like
peptide-1 (GLP-1), resistin, pancreatic polypeptide, and insulin-
like growth factor binding protein-3 (IGFBP-3).
Table 2 demonstrates that pancreatic islet peptides other than
amylin (insulin, C-peptide, and glucagon) were all significantly
elevated in serum of obese versus lean subjects (p < 0.0001
in all cases). Levels of the incretin hormone gastric inhibitory
polypeptide (GIP) were also higher (p = 0.001), in accord with
the higher insulin levels in obese versus lean subjects.
Consistent with numerous prior reports (Bjorbaek and
Kahn, 2004; Trujillo and Scherer, 2006), the adipocyte-derived
hormones leptin and adiponectin were reciprocally altered by
obesity, such that leptin levels were 3.8-fold higher in obese
subjects (p < 0.0001), whereas adiponectin levels were 37%
lower (p < 0.0001). Among hormones that have been implicated
in control of food intake, the gut-derived orexigenic peptide ghre-
lin was 30% lower in serum of obese subjects (p < 0.0001),
whereas neuropeptideY (NPY) (orexigenic) and peptideYY (PYY)
(presumed antiorexigenic) were 15% and 37% higher, respec-
tively (p % 0.0006). Human growth hormone (hGH) trended
lower (p = 0.039), and total IGF-1, IGFBP-1, and IGFBP-2 were
all dramatically lower in serum of obese subjects (p < 0.0001)
(Table 2). We also measured free IGF-1 and found this analyte
to be markedly lower in the obese subjects (p = 0.01; Table 2).
Among the pro- and anti-inflammatory cytokines measured,
neither IL-6 nor TNF-a differed between obese and lean subjects,
whereas IL-10 trended lower in the obese subjects (p = 0.025). In
contrast, C-reactive protein (CRP) levels were 5.3-fold higher in
obese subjects (p < 0.0001) (Table 2). Both IL-6 and TNF-a
have been previously implicated in the development of insulin
resistance (Wellen and Hotamisligil, 2005; Shoelson et al.,
2006), and CRP has been strongly linked to cardiovascular
disease (Ridker et al., 1998) as well as to components of the
‘‘metabolic syndrome,’’ including insulin resistance, although
a recent study suggests that obesity is the major determinant of
the CRP/insulin resistance relationship (Kahn et al., 2006).
Conventional Metabolites
Median fasting blood glucose levels were modestly elevated in
obesecompared to leansubjects (105.0mg/dl versus100.5mg/dl,
p=0.005).Obesesubjects hadsignificantly higher levelsof nones-
terified free fatty acids (p=0.004) and triglycerides (p<0.0001) and
substantially lower high-density lipoprotein (HDL) cholesterol
(p < 0.0001). Levels of ketones (total and b-hydroxybutyrate),
byproducts of lipid catabolism, were not different between the
groups, whereas levels of pyruvate (p < 0.0001) and lactate (p =
0.0006), products of carbohydrate catabolism, were higher in
serum of obese subjects (Table 2). These findings appear consis-
tent with the increase in RQ observed in the obese subjects
(Table 1).
Metabolites Measured by Mass Spectrometry
Consistent with the general picture of perturbation of lipid
homeostasis gained from analysis of conventional metabolites,
clear differences in individual free and total fatty acids were
observed in obese compared to lean subjects (Table 2). Amongfree fatty acids, five of the eight species measured were signifi-
cantly higher in obese compared to lean subjects (C14:0,
C16:0, C16:1, C18:1, C20:4; p values ranging from 0.0004 to
0.01). The rise in C16:1 (palmitoleate) in insulin-resistant and
obese subjects is of interest in light of a recent study suggesting
that C16:1 promotes insulin sensitivity in skeletal muscle (Cao,
et al., 2008). Total fatty acid species were more dramatically
increased in the obese subjects, with 13 of the 17 analytes
clearly increased in serum of obese subjects, with p < 0.0001
for 9 of these, including C16:1 (Table 2).
We also measured amino acids and acylcarnitines in the serum
by tandem mass spectrometry (MS/MS) and organic acids in the
urine by gas chromatography/mass spectrometry. Among a total
of 16 amino acids measured in the serum, 7 were not different in
obese versus lean subjects (citrulline, histidine, methionine, orni-
thine, proline, serine, tryptophan). Eight other amino acids were
dramatically elevated in obese versus lean participants (alanine,
valine, leucine/isoleucine, phenylalanine, tyrosine, glutamate/
glutamine, aspartate/asparagine, arginine; p% 0.0007), whereas
glycine levels were lower in obese subjects (p = 0.0007) (Table
2). Among 37 acylcarnitine species measured, only 4 were signif-
icantly higher in obese subjects (C3, C5, C6, C8:1; p % 0.009)
(Table 2). Finally, among 20 organic acids measured in urine by
GC/MS, 15werenot different in obese versus lean subjects (meth-
ylmalonate, succinate, methylsuccinate, fumarate, glutarate, bu-
tyrylglycine, malate, adipate, hexanoyl glycine, suberate, orotate,
homovanillic, citrate, pyruvate, lactate). Levels of ethylmalonate
were significantly higher, and levels of isobutyryl glycine, isovaleryl
glycine, and a-ketoglutarate were lower in urine samples from
obese compared to lean subjects (Table 2).
A BCAA-Related Metabolic ‘‘Signature’’ in Obese
Subjects
We used principal components analysis (PCA) to consolidate the
metabolites referenced above into 18 components, which were
analyzed for differences between obese and lean subjects.
Remarkably, the component that showed the strongest differ-
ences between obese and lean groups was comprised of
a combination of BCAA (leucine/isoleucine and valine), methio-
nine, Glx (glutamate/glutamine), the aromatic amino acids
phenylalanine and tyrosine, and C3 and C5 acylcarnitines
(p < 0.0001). Furthermore, evaluation of the association between
this BCAA-related metabolite component and HOMA reveals
a significant linear relationship (Figure 1; r = 0.58, p < 0.0001),
even after adjusting for obese versus lean status using a partial
Spearman correlation coefficient (r = 0.33, p < 0.0001). To further
ensure the independent relationship of the BCAA-relatedmetab-
olite component with HOMA, we performed correlation analyses
stratified by obese/lean status and adjusted for age, race, and
sex, which revealed the same magnitude of correlation in
obese subjects as in the total subject population (unadjusted
Spearman: r = 0.36, p = 0.002; partial Spearman adjusted for
age, race, andsex: r =0.33, p=0.007),with nosignificant relation-
ship in lean subjects (unadjusted Spearman: r = 0.17, p = 0.18;
partial Spearman adjusted for age, race, and sex: r = 0.13,
p = 0.30), as might be anticipated due to the limited variability
of insulin sensitivity within the normal range in this group.
We note the presence of an outlier among the obese subjects
with both severe insulin resistance and a very high score for theCell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 313
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Obese Lean P value
Hormones n = 74 n = 67
Insulin (mUI/ml) 22.01 (15.71, 30.14) 9.99 (8.36, 13.51) <0.0001
C peptide (ng/ml) 3.62 (2.71, 4.58) 1.90 (1.59, 2.34) <0.0001
Glucagon (pg/ml) 91.18 (79.63, 120.72) 68.92 (56.08, 89.58) <0.0001
GIP (pg/ml) 43.99 (26.28, 62.25) 29.58 (20.39, 44.90) 0.0011
Leptin (ng/ml) 29.67 (19.71, 44.08) 7.83 (3.67, 14.77) >0.0001
Adiponectin (mg/ml) 6.06 (4.00, 8.94) 9.62 (6.96, 14.85) <0.0001
Ghrelin (pg/ml) 674.09 (504.85, 881.23) 965.75 (636.23, 1269.37) <0.0001
NPY (pM) 51.18 (43.74, 61.72) 44.47 (35.05, 52.50) 0.0006
PYY (pg/ml) 141.88 (112.55, 168.19) 103.36 (88.74, 126.14) <0.0001
Resistin (ng/ml) 3.84 (3.3, 4.8) 3.64 (2.9, 4.9) 0.34
Amylin (pM)a 4.78 (0.00, 16.03) 3.94 (0.00, 31.52) 0.81
GLP-1 (pg/ml)b 24.21 (17.62, 35.71) 28.36 (15.75, 92.69) 0.42
PP (pM) 24.26 (14.46, 44.99) 24.46 (11.83, 52.38) 0.63
Growth hormone axis (ng/ml)
Growth hormone 0.08 (0.00, 0.46) 0.30 (0.01, 1.64) 0.0394
Total IGF-1 134.26 (93.26, 184.64) 250.20 (153.34, 325.16) <0.0001
IGFBP-1 8.25 (3.47, 17.21) 19.75 (12.21, 28.53) <0.0001
IGFBP-2 244.27 (66.66, 362.42) 603.57 (384.00, 960.54) <0.0001
IGFBP-3 3290.0 (2920.8, 3804.4) 3301.0 (2771.9, 4041.0) 0.89
Free IGFc 0.4595 (0.3365, 0.713) 0.558 (0.406, 0.926) 0.01
Cytokines n = 74 n = 67
Interleukin-6 (pg/ml) 7.62 (4.31, 11.35) 8.18 (5.80, 10.89) 0.32
TNF-a (pg/ml) 9.61 (6.73, 14.89) 6.93 (5.07, 14.1) 0.19
C-reactive protein (mg/l) 4.48 (2.35, 7.55) 0.85 (0.45, 1.35) <0.0001
Interleukin-10 (pg/ml)a 0.91 (0.01, 2.87) 1.85 (0.25, 3.11) 0.0251
Conventional metabolites n = 74 n = 67
Fasting glucose (mg/dl) 105.0 (97.5, 116.0) 100.5 (92.5, 106.0) 0.005
Free fatty acid (mmol/l) 0.58 (0.45, 0.72) 0.43 (0.33, 0.68) 0.004
Ketones (mmol/l) 82.5 (46.5, 120.0) 55.5 (39.5, 140.5) 0.28
Cholesterol (mg/dl) 191.0 (174.5, 213.0) 188.5 (161.5, 223.0) 0.67
LDL cholesterol (mg/dl) 119.3 (103.0, 139.7) 105.8 (86.2, 124.8) 0.02
Triglyceride (mg/dl) 106.5 (77.0, 163.0) 63.5 (46.0, 89.0) <0.0001
HDL cholesterol (mg/dl) 49.9 (38.7, 58.7) 62.2 (54.5, 77.6) <0.0001
Plasma lactic acid (mM) 1.3 (1.2, 1.6) 1.1 (0.86, 1.4) 0.0006
Plasma pyruvic acid (mM) 0.12 (0.10, 0.15) 0.09 (0.07, 0.11) <0.0001
b-hydeoxybutyrate (mmol/l) 47.8 (27.5, 73.0) 35.0 (22.5, 100.5) 0.35
Amino acids (mM) n = 74 n = 67
Valine 281.4 (249.2, 332.9) 235.3 (204.1, 257.0) <0.0001
Leucine/Isoleucine 170.0 (150.2, 200.8) 149.0 (132.5, 176.6) <0.0001
Glutamate/Glutamine 118.4 (91.4, 143.7) 81.2 (66.7, 95.2) <0.0001
Glycine 282.6 (245.6, 319.6) 328.4 (265.6, 403.0) 0.0007
Alanine 433.4 (394.5, 492.3) 367.3 (297.1, 420.0) <0.0001
Phenylalanine 72.6 (66.3, 78.9) 61.6 (55.1, 68.8) <0.0001
Tyrosine 79.5 (68.5, 90.0) 67.1 (56.7, 73.5) <0.0001
Aspartate/Asparagine 20.1 (17.3, 23.8) 16.5 (13.5, 19.7) <0.0001
Arginine 135.2 (116.5, 148.5) 115.3 (101.6, 137.0) 0.0007
Citrulline 32.0 (27.9, 40.3) 36.3 (30.5, 40.7) 0.04314 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.
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Obese Lean P value
Histidine 81.6 (73.5, 88.9) 81.9 (71.9, 91.6) 0.57
Methionine 27.5 (25.1, 30.7) 27.6 (24.2, 30.9) 0.68
Ornithine 69.6 (55.3, 80.8) 64.8 (53.3, 71.8) 0.18
Proline 176.4 (155.4, 231.5) 158.1 (138.4, 201.7) 0.02
Serine 115.6 (100.7, 131.9) 116.7 (102.2, 138.6) 0.69
Acylcarnitines (mM) n = 74 n = 67
Propionyl (C3) 0.45 (0.35, 0.54) 0.38 (0.28, 0.48) 0.0034
Isovaleryl/2-methylbutyryl (C5) 0.12 (0.10, 0.16) 0.09 (0.07, 0.13) 0.0004
Hexanoyl (C6)a 0.10 (0.04, 0.16) 0.06 (0.00, 0.11) 0.0089
Octenoyl (C8:1) 0.28 (0.19, 0.35) 0.18 (0.16, 0.27) 0.0006
Organic acids (mmol/mol) n = 70 n = 67
Ethyl malonate 3.03 (2.41, 4.02) 2.61 (2.28, 2.95) 0.0054
Isobutyryl glycine 0.40 (0.26, 0.58) 0.53 (0.40, 0.86) 0.001
Isovaleryl glycine 0.62 (0.42, 0.95) 0.92 (0.53, 1.33) 0.0031
a-Ketoglutarate 4.72 (3.37, 7.26) 8.19 (4.21, 12.75) 0.0005
Free fatty acids (mM) n = 74 n = 67
Octanoic C8:0 ND ND ND
Decanoic C10:0 ND ND ND
Lauric C12:0 ND ND ND
Myristic C14:0 9.98 (7.9, 12.7) 7.45 (5.8, 11.5) 0.01
Myristoleic C14:1 ND ND ND
Palmitic C16:0 141.3 (103.4, 176.5) 101.3 (73.3, 150.5) 0.0004
Palmitoleic C16:1 21.5 (13.4, 35.0) 14.6 (8.0, 25.4) 0.001
Stearic C18:0 42.4 (32.2, 55.0) 36.9 (27.5, 53.2) 0.3
Oleic C18:1 206.4 (156.2, 270.6) 157.9 (103.7, 241.2) 0.002
Linoleic C18:2 81.3 (62.9, 99.7) 75.8 (46.3, 94.3) 0.087
a-Linolenic C18:3 6.87 (4.8, 9.7) 5.68 (3.9, 8.5) 0.048
Arachidic C20:0 ND ND ND
Gondoic C20:1 ND ND ND
Eicosadienoic C20:2 ND ND ND
Dihomogamma-linolenic C20:3 ND ND ND
Arachidonic C20:4 5.98 (4.3, 7.8) 4.6 (3.3, 6.8) 0.006
Docosahexaenoic C20:6 ND ND ND
Total fatty acids (mM) n = 73 n = 67
Octanoicd C8:0 29.70 (26.23, 39.90) 36.66 (27.47, 43.77) 0.073
Decanoic C10:0 5.30 (4.43, 6.58) 4.96 (4.05, 6.43) 0.079
Lauric C12:0 10.12 (7.62, 16.85) 8.59 (6.33, 13.79) 0.05
Myristic C14:0 102.3 (77.4, 155.7) 71.9 (50.2, 111.2) <0.0001
Myristoleic C14:1 7.2 (5.3, 10.8) 4.7 (3.1, 7.2) <0.0001
Palmitic C16:0 1744.9 (1398.3, 2169.6) 1234.8 (982.1, 1591.5) <0.0001
Palmitoleic C16:1 410.2 (295.5, 546.3) 206.9 (174.4, 323.9) <0.0001
Stearic C18:0 880.8 (748.5, 1033.5) 712.68 (601.5, 789.9) <0.0001
Oleic C18:1 2762.8 (2304.2, 3382.2) 1944.4 (1692.4, 2481.3) <0.0001
Linoleic C18:2 4100.4 (3050.7, 5027.9) 3449.4 (2561.9, 4034.8) 0.0038
a-Linolenic C18:3 78.9 (63.7, 95.9) 54.6 (41.9, 78.1) <0.0001
Arachidic C20:0 5.37 (4.58, 7.72) 5.86 (4.39, 8.05) 0.51
Gondoic C20:1 14.4 (11.7, 19.2) 11.2 (8.5, 14.6) 0.0003
Eicosadienoic C20:2 22.8 (17.0, 26.2) 16.5 (13.8, 19.4) 0.0002
(Continued on next page)Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 315
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Obese Lean P value
Dihomogamma-linolenic C20:3 220.9 (185.9, 279.7) 140.0 (114.5, 180.2) <0.0001
Arachidonic C20:4 850.44 (685.7, 1098.3) 615.0 (528.1, 871.1) <0.0001
Docosahexaenoic C20:6 181.8 (140.4, 243.5) 142.4 (111.1, 177.8) 0.0016
All results presented as medians (25th, 75th percentile). ND, not detectable.
aMetabolite has > 10% zero cells.
bGLP-1: n = 52 for obese, n = 61 for lean.
c Free IGF-1: n = 90 for obese, n = 65 for lean.
dOctanioc: n = 72 for obese, n = 66 for lean.BCAA factor (Figure 1). Importantly, when this outlier was
removed, we observed the same magnitude of relationship
between the BCAA factor and HOMA, even when adjusted for
obese/lean status, age, race, and sex. Thus, this outlier is not
a sole driver of the relationship.
Effects of BCAA Supplementation in Animal Feeding
Studies
To test the idea that BCAA can make a direct contribution to
obesity-related comorbidities such as insulin resistance and
glucose intolerance, we fed Wistar rats on one of three diets:
HF, HF/BCAA, or standard chow (SC) (Table S1). After 13 weeks
of feeding, HF-fed rats had gained 170% relative to starting body
weight, whereas HF/BCAA- and SC-fed rats had gained 151%
and 149%, respectively (Figure 2A; p < 0.039 for HF versus
HF/BCAA or SC groups). The difference in body weight between
the HF and HF/BCAA groups was due to different rates of food
intake, as HF- and SC-fed rats consumed an average of 746
and 782 kcal/rat/week over the 13 week feeding period, whereas
HF/BCAA-fed rats consumed 666 kcal/rat/week (Figure 2B); the
identical weight gain in the HF/BCAA and SC groups despite
different rates of food intake is likely due to the higher rate of
energy expenditure in the SC-fed animals (see below).
Analysis of BCAA and acylcarnitine levels in the blood revealed
80%–150% increases in leucine/isoleucine and 48%–109%
increases in valine in HF/BCAA-fed rats relative to the other
two groups at 3, 6, and 9 weeks of feeding (Figures S1A and
S1B). Interestingly, over the same time periods, HF-fed rats
had lower levels of plasma C3 (39%–51%, p < 0.01) and C5
(29%–36%, p < 0.08) acylcarnitines compared to SC animals,
consistent with a large decrease in RER/RQ that indicates an316 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.increased reliance on lipid oxidation for energy production
(see below). In contrast, C3 and C5 acylcarnitines were raised
to the levels of SC rats in plasma animals fed on the HF/BCAA
diet, despite unchanged RER/RQ relative to HF rats (Figures
S1C and S1D). Further, complete analysis of acylcarnitine
species by MS/MS analysis reveals a clear increase in C3 and
C5 acylcarnitines in HF/BCAA-fed animals relative to all other
groups in skeletal muscle (see below). These results, coupled
with the known BCAA catabolic pathways, suggest that C3
and C5 acylcarnitines are direct products of BCAA catabolism
that accumulate with modest BCAA overfeeding.
Despite a rate of body weight gain equivalent to the SC group,
HF/BCAA-fed rats were equally insulin resistant as HF-fed rats
after 15 weeks of diet feeding based on glucose (IPGTT) (Figures
2C and S2A) and insulin (data not shown) tolerance tests. Also,
bothHF- andHF/BCAA-fed rats exhibited impairedphosphoryla-
tion (activation) of Akt/protein kinaseB in skeletalmuscle (Figures
2D and 2E) and liver (Figures 2F and 2G) in response to an acute
insulin injection. These experiments demonstrate a contribution
of BCAA to development of insulin resistance that is independent
of body weight. To exclude the possibility that insulin resistance
in the HF/BCAA-fed group was due to the HF diet rather than the
supplemented BCAA, we performed an independent feeding
study involving ad-lib feeding of SC, HF, or HF/BCAA diets plus
a fourth group of animals pair-fed the HF diet (HF/PF) in amounts
that matched the lower rate of food intake of the HF/BCAA
group. Consistent with the data of Figure 2, rats fed ad-lib on
theHF/BCAAdiet gained lessweight and ate less food than those
fed ad-lib on the HF diet; as expected, HF/PF rats had body
weights identical to the HF/BCAA group and not significantly
different from the SC-fed group (Figures S3A and S3B). IPGTTFigure 1. A BCAA-Related Metabolic ‘‘Signature’’ Correlates
with Insulin Sensitivity
The figure shows the relationship between insulin sensitivity (HOMA)
and a principal component comprised of BCAA-related metabolites,
including the BCAAs valine, leucine, and isoleucine; Glx (glutamate
and glutamine); the aromatic amino acids phenylalanine and tyrosine;
and C3 and C5 acylcarnitines (See Experimental Procedures and
Results for further description). Diamonds, lean subjects (n = 67);
squares, obese subjects (n = 74).
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clear insulin resistance in the HF- and HF/BCAA-fed animals,
but not in theHF/PFor SCgroups (FiguresS3CandS3D), proving
that moderate fat intake is not sufficient to induce insulin resis-
tance, but requires the presence of an additional factor such as
intake of BCAA.
A third feeding studywascarried out inwhich ratswere allowed
to feed ad-lib either on SC diet or SC supplemented with BCAA
(SC/BCAA) (Table S1) for 12–16 weeks. These studies revealed
no differences in body weight, insulin sensitivity assessed by
IPGTT, or insulin tolerance tests between the twogroups, despite
clear increases in BCAA and C3 and C5 acylcarnitine levels in
the SC/BCAA compared to the SC group (Figure S4). These
results demonstrate that the effects of BCAA on feeding behavior
and insulin action occur only in the context of a diet that is also
high in fat.
Effects of BCAA Supplementation on Insulin Signaling
Mechanisms
Because BCAA have been reported to interfere with insulin
signaling via stimulation ofmTOR andS6K1 and phosphorylation
of IRS1 on serine residues (Um et al., 2006; Tremblay et al.,
2007a, 2007b; Krebs et al., 2007), we investigated the contribu-
tion of this pathway to development of insulin resistance in rats
fed on the HF, HF/BCAA, or SC diets. In animals fed on the
various diets, fasted for 48 hr, and then refed on the original
diet for 4 hr, we found clear increases in phospho-mTORSer2448,
phospho-S6K1Thr389, and phospho-IRS1Ser302 in skeletal muscle
of HF/BCAA-fed rats compared to either the HF or SC groups
(Figures 2H–2L). Phospho-IRS1Ser307 levels were raised in both
the HF and HF/BCAA groups relative to SC in the fasted/refed
state, and these levels were also specifically elevated in muscles
of fasted HF/BCAA-fed rats (Figures 2K, 2L, and S2B).
Fasted and refed HF and HF/BCAA rats had equally increased
levels of insulin compared to SC animals (p < 0.04; data not
shown), further proving insulin resistance. We also examined
phosphorylation of IRS1Ser636/639 and IRS1Ser1101, which have
been implicated in diet-induced insulin resistance (Tremblay
et al., 2007a; Krebs et al., 2007), but found no differences in
the levels of these modified proteins among the various dietary
groups (data not shown).
To eliminate the possibility that the increase in serine/threonine
phosphorylation of mTOR, S6K1, and IRS1 was simply due to
acute feeding of BCAA, we also performed a ‘‘crossfeeding’’
study, in which HF/BCAA-fed rats were fasted and refed on HF
diet while HF- and SC-fed rats were fasted and refed on the
HF/BCAA diet. Following these manipulations, mTOR, S6K1,
and IRS1Ser302 levels were all significantly elevated in the HF/
BCAA-fed group refed on HF diet compared to the other two
groups refed on HF/BCAA diet (Figure S2C), demonstrating sus-
tained alterations in insulin signaling in the HF/BCAA-fed animals
thatwas not due to acute ingestion of excessBCAA in the refeed-
ing period. We measured food intake during both the same-diet
refeeding and crossfeeding studies, and found no differences in
food intake among the experimental groups (data not shown),
thereby eliminating this as a contributing factor to the data shown
in Figure S2C. Finally, we performed studies on a cohort of rats
fed the HF diet with 26% supplementation of 18 amino acids
(HF/AA, Table S1), such that the diet was isonitrogenous withthe HF/BCAA diet. In this set of experiments, the HF and HF/AA
groups gained weight at the same rate (187% and 176% weight
increases over 16 weeks, respectively), whereas the HF/BCAA
group again gained weight at a slow rate similar to the SC-fed
animals (146% and 131%, respectively). These results show
a specific effect of BCAA supplementation that is not a general
consequence of increased protein feeding.
To further investigate the role of enhanced mTOR/S6K1/IRS1
signaling in HF/BCAA-mediated insulin resistance, we per-
formed IPGTT experiments in animals treated with the mTOR
inhibitor rapamycin. Rapamycin injection clearly reversed the
glucose intolerance of HF/BCAA-fed rats, but had no normalizing
effect on glucose clearance in the HF rats (Figure 2M), providing
a direct demonstration of the importance of altered mTOR/S6K1
signaling in mediating HF/BCAA-induced insulin resistance.
Physiologic Measurements in Animal Feeding Studies
Two recent studies have reported changes in energy expenditure
in response to transgenic (She et al., 2007) or nutritional (Zhang
et al., 2007) manipulation of BCAA or leucine levels, respectively.
To investigate this in our own models, we measured total energy
expenditure (VO2) and RER/RQ in rats fed on the HF/BCAA, HF,
and SC diets. Feeding of either the HF or HF/BCAA diets lowered
VO2 in the dark cycle only and RER/RQ in both the dark and light
cycles, to similar extents as the SC diet (Figure 3). However, no
differenceswere observed in these variables inHF/BCAA- versus
HF-fed rats.
Mechanisms Underlying BCAA Effects in HF Diet
Finally, we addressed the question ofwhyBCAA supplementation
of HF but not SC diet contributes to insulin resistance. Recent
studies have demonstrated that HF feeding causes accumulation
of a broad range of acylcarnitine species in skeletal muscle, indic-
ative of incomplete oxidation of fatty acids in the mitochondria
(Koves et al., 2008; Muoio and Newgard, 2008; An et al., 2004).
Accumulation of these incompletely oxidized lipid species in
muscle mitochondria may contribute to insulin resistance, since
two maneuvers that cause their clearance, exercise and trans-
genic knockout of malonyl CoA decarboxylase, lead to enhanced
insulinaction (Kovesetal., 2008;MuoioandNewgard,2008).Addi-
tion of BCAA to SC diet resulted in no change in a broad array of
acylcarnitine species in skeletal muscle relative to animals fed
on SC diet alone (Figure 4A). Consistent with our prior studies,
HF feeding caused significant accumulation of multiple acylcarni-
tines in muscle relative to the SC or SC/BCAA groups (Figure 4A).
Surprisingly, the HF/BCAA diet also caused accumulation of the
same array of muscle acylcarnitines, despite the fact that the HF/
BCAA animals weighed less and consumed less food than the
HF-fed animals. HF/BCAA feeding also caused increased skeletal
muscle C3 and C5 acylcarnitine levels relative to all other groups.
We also compared the effect of BCAA supplementation of the
SC and HF diets at the level of mTOR activation in skeletal
muscle from fasted rats. Addition of BCAA to the SC diet had
no effect on mTOR activity relative to SC feeding alone, whereas
BCAA addition to the HF diet increased mTOR activity relative to
feeding of HF alone (Figures 4B and 4C). For these studies, the
additional control of an isonitrogenous, pan-amino acid-supple-
mented diet (HF/AA) was included, and muscle samples from
these animals also had lower levels of phospho-mTOR thanCell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 317
Cell Metabolism
Metabolic Signatures, Obese Versus LeanFigure 2. Effects of BCAA Supplementation on Body Weight, Food Intake, and Insulin Signaling
(A–B) Body weight expressed as percent of initial weight (A) and food intake expressed as kcal/rat/week (B). Rats were fed on SC, HF diet, or HF/BCAA diets for
12–16weeks. Data for (A) and (B) represent 5–9 animals per group. In (A), HFwas different fromboth the SC andHF/BCAA groups at all time points, with p < 0.036.
In (B), HF/BCAA was different from both the SC and HF groups at all time points, with p < 0.006.
(C) IPGTT; n = 5–9 rats/group. * indicates that the SC group was different from the other two groups, with p < 0.036.
(D) Representative immunoblot of p-AKT levels in skeletal muscle 30 min after an acute insulin bolus in overnight-fasted rats.
(E) Quantitative summary of muscle p-AKT studies, expressed as ratio of insulin-stimulated to noninsulin-stimulated conditions and normalized to total AKT
protein.
(F) Representative immunoblot of p-AKT levels in liver, 30 min after an acute insulin bolus in overnight-fasted rats.318 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.
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Metabolic Signatures, Obese Versus LeanFigure 3. Indirect Calorimetry Analysis
(A) RER/RQ measured continuously over a 34 hr period that includes a typical dark/light cycle.
(B) Average RER/RQ.
(C) VO2 measured continuously over a 34 hr period that includes a typical dark/light cycle.
(D) Average VO2. For all panels, *p < 0.05, SC group compared to the other two groups.the HF/BCAA group, further demonstrating a specific effect of
BCAA as opposed to overall nitrogen load.
Finally, the literaturecontainsseveral examplesofparallel regu-
lation of JNK and mTOR and is suggestive of crosstalk between
these proteins (Hiratani et al. 2005;Mussig et al., 2005). To inves-
tigate a possible involvement of JNK in HF/BCAA-mediated
impairment of insulin action, muscle samples from all of the fore-
going dietary groups were analyzed for JNK activity (Figures 4D
and 4E). Relative to SC-fed rats, SC/BCAA animals exhibited no
increase in JNK activity. HF or HF/AA feeding caused a modest
but significant increase in JNK activity relative to the SC groups,
whereas HF/BCAA feeding caused a larger increase that was
significant compared to all other groups.
DISCUSSION
In the present study, we have applied a comprehensive set of
analytical tools to gain a deeper understanding of biochemical,endocrine, inflammatory marker, and physiologic differences
between obese and lean humans. A number of the obesity-
related changes described herein confirmprior studies, including
the higher levels of leptin and the lower levels of adiponectin and
ghrelin; the increase in the inflammatory/cardiovascular risk
marker, CRP; and the presence of insulin resistance in the obese
subjects (Bjorbaek and Kahn, 2004; Trujillo and Scherer, 2006;
Reaven, 2006; Ridker et al., 1998; Hosoda et al., 2006). However,
other findingswere not clearly anticipated, either due to inconsis-
tency in the literatureor becauseunanticipatedpatterns emerged
from our analysis of multiple markers in a single study.
Whereas prior studies have generally indicated that hGH levels
are reduced inobesity (Scacchi et al., 1999;Wittchen et al., 2005),
IGF-1 levels have been variously reported to be reduced (Marin
et al., 1993; Maccario et al., 1999; Schneider et al., 2006) or
unchanged (Rasmussen et al., 1994; Maccario et al., 2001). In
the current study, we found that obesity was associated with
decreases in hGH, IGF-1, IGFBP-1, and IGFBP-2. We believe(G) Quantitative summary of liver p-AKT studies, expressed as ratio of insulin-stimulated to noninsulin-stimulated conditions and normalized to total AKT protein
levels. For (E) and (G), * indicates that SC-fed animals had higher levels of p-AKT than the other two groups, with p < 0.033.
(H–L) p-mTOR2448, representative immunoblot (H); p-P70S6K1389, representative immunoblot (I); p-IRS1Ser302, representative immunoblot (J); p-IRS1Ser307,
representative immunoblot (K). Quantitative summary of phosphoproteins normalized to total levels of mTOR, p70S6K1, or IRS1, respectively, is shown in (L).
Data in (H)–(L) are for skeletal muscle samples from 3–5 animals/group fed on the three diets, fasted for 48 hr, and then refed on the same diets for 4 hr. * in
(L) indicates higher levels of phosphoproteins in the HF/BCAA group compared to the other two groups, with p < 0.05.
(M) Rapamycin treatment reverses insulin resistance in HF/BCAA-fed but not HF-fed rats. Data shown are for 5–7 animals per group. *p < 0.05 for comparison of
HF-fed, rapamycin treated or HF/BCAA-fed, nontreated groups with the SC, rapamycin-treated, or HF/BCAA, rapamycin-treated groups.Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 319
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Metabolic Signatures, Obese Versus LeanFigure 4. BCAA Supplementation of HF Diet Causes Accumulation of Acylcarnitines in Skeletal Muscle and Chronic Activation of mTOR
and JNK
(A) Skeletal muscle samples were collected from animals fed on the indicated diets and used for acylcarnitine analysis byMS/MS. Data represent themean ±SEM
for six animals per group. *p < 0.05 for comparison of SC and SC/BCAA to HF and HF/BCAA groups. #p < 0.05 for comparison to HF/BCAA group.
(B) Representative p-mTOR2448, immunoblot in muscle from overnight-fasted SC, SC/BCAA, HF, HF/AA, and HF/BCAA-fed rats.
(C) Quantitative summary of p-mTOR2448 analyses.
(D) Representative p-cJUNSer63 immunoblot in muscle from the same sets of animals studied in (B).
(E) Quantitative summary of p-cJUN analyses. *p < 0.05 for comparison of HF/BCAA to the other groups. #, p < 0.05 for comparison of SC and SC/BCAA
to the other groups. In (C) and (E), n = 6–9 animals/group.that these data in aggregate indicate a reduction in bioavailable
IGF-1, supported by our finding of lower levels of free IGF-1 in
obese compared to lean subjects (Table 1).
Hyperlipidemia has been ascribed a role in the pathogenesis of
insulin resistance (Muoio andNewgard, 2008;Morino et al., 2006),
and in the current study, several perturbations of lipid homeo-
stasis were noted in obese subjects. Among individual free fatty
acids, significant but modest increases were noted in endoge-
nously synthesized (‘‘nonessential’’) long-chain species (C16:0,
C16:1, C18:1) in obese subjects, but not in polyunsaturated
(‘‘essential’’) species such as C18:2 (linoleic) or C18:3 (linolenic).
In contrast, all of these fatty acid species and several more were320 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.dramatically elevated in the total fatty acid pool in obese subjects;
thispool largely represents fattyacids thatcirculate in triglycerides
or other esterified species, consistent with the strong increase
in TG levels in the obese subjects. Accumulation of fatty acids
in esterified products may have been driven by the increased
propensity of the obese subjects to oxidize glucose and/or amino
acids relative to lipids, consistent with their increased RQ. This
would lead to increased tissue malonyl CoA levels and suppres-
sion of fatty acid oxidation in liver (McGarry, 2002), partitioning
lipids toward esterification pathways. Sequestration of a large
and diverse pool of fatty acids in esterified species would allow
an enhanced rate of their delivery to peripheral tissues, possibly
Cell Metabolism
Metabolic Signatures, Obese Versus LeanFigure 5. Schematic Summary of BCAA Overload Hypothesis
In the physiological context of overnutrition and low IGF-1 levels, as found in our obese subjects, circulating BCAAs rise, leading to increased flux of these amino
acids through their catabolic pathways. We detected changes in several of the intermediary metabolites of the BCAA catabolic pathway in obese subjects, as
indicated by the symbol *. A consequence of increased BCAA levels is the activation of the mTOR/S6K1 kinase pathway and phosphorylation of IRS1 onmultiple
serines, contributing to insulin resistance. In addition, increased BCAA catabolic flux may contribute to increased gluconeogenesis and glucose intolerance via
glutamate transamination to alanine.contributing to accumulation of lipid-derived metabolites such as
diacylglyerols, ceramides, ketones, prostaglandins, and incom-
pletely oxidized lipids that can impact insulin signaling (Muoio
and Newgard, 2008; Morino et al., 2006; Summers, 2006).
We also identified a cluster of obesity-associated changes in
specific amino acid, acylcarnitine, and organic acid metabolites
in obese compared to lean subjects that was associated with
insulin resistance. We hypothesize that these changes may
reflect an overload of BCAA catabolism in obese subjects.
Subjects that become obese on a typical American diet, as in
the current study, consumehigh levels of fat andprotein, anddie-
tary protein is comprised of >20% BCAA (Layman and Walker,
2006).Wepropose thatwhen coupledwith overnutrition, the rela-
tive IGF-1 deficiency that we document in the obese subjects
forces the now-expanded circulating BCAA pool to be diverted
away from protein synthesis and into catabolic pathways.
Consistent with this hypothesis, we observed that levels of the
BCAAs valine and leucine/isoleucine were 20% and 14% higher,
respectively, in obese compared to lean subjects (p < 0.0001 in
both cases). As summarized in Figure 5, other changes also fit
the model:
(1) The decreased levels ofa-ketoglutarate and the increased
levels of glutamate. a-ketoglutarate will be consumed and
glutamate synthesized in the first step of BCAA catabo-
lism, transamination.Ce(2) The significant and specific increases in C3 and C5
acylcarnitine levels. C5 acylcarnitines are comprised of
a-methylbutyryl and isovalerylcarnitine species;a-methyl-
butyryl CoA and isovaleryl CoA are intermediates in mito-
chondrial isoleucine and leucine catabolism, respectively,
and these intermediates equilibrate with their cognate
acylcarnitine esters. C3 acylcarnitine reflects the pro-
pionyl CoA pool; propionyl CoA is a byproduct of both
isoleucine and valine catabolism.
(3) A high rate of flux through BCAA catabolic pathways and
accumulation of glutamate may increase transamination
of pyruvate to alanine. Increases in alanine, a highly gluco-
neogenic amino acid, could contribute to development of
glucose intolerance in obesity. Indeed, circulating pyru-
vate and alanine levels are clearly elevated in the obese
subjects.
(4) The aromatic amino acids, phenylalanine and tyrosine, are
elevated in obese compared to lean subjects. This may be
explained by the fact that the ‘‘large neutral amino acids’’
(tryptophan, phenylalanine, tyrosine, leucine, isoleucine,
valine), encompassing both BCAA and aromatic amino
acids, compete for transport into mammalian cells by
the large neutral amino acid transporter (LAT1) (Fernstrom,
2005). Assuming that chronic elevations in BCAA
impair transport of aromatic amino acids into cells and
tissues, this could contribute to reduced production ofll Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 321
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phan) and catecholamines (derived from phenylalanine
and tyrosine) in the central nervous system. Indeed, imbal-
ances in the serum molar ratio of tryptophan to its large
neutral amino acid competitors (sum of phenylalanine +
leucine+ isoleucine+valine+ tyrosine), the so-called ‘‘tryp-
tophan ratio,’’ have been related to depression (Chevalier
et al., 2005; Capuron et al., 2002) and obesity (Ashley
et al., 1985; Breum et al., 2003). In the present study, the
tryptophan ratio was depressed in obese versus lean
subjects (0.138 versus 0.169, respectively, p < 0.0001),
driven by elevations in phenylalanine, tyrosine, leucine,
isoleucine, and valine (Table 2) coupled with unchanged
median tryptophan levels (obese 83.6 mM, lean 88.2 mM).
(5) Finally, the exaggerated insulin secretion response to
glucose in obese subjects may be due to potentiation of
glucose-stimulated insulin secretion by BCAA (Newgard
and Matschinsky, 2001).
It has been known for some time that obesity is accompanied
by an increase in circulating levels of multiple amino acids,
including BCAA (Felig et al., 1974; Chevalier et al., 2005; Um
et al., 2006; Tremblay et al., 2007b; Krebset al., 2007). The effects
of BCAA, particularly leucine, to activate mTOR and S6K1 are
also well known (Um et al., 2006; Tremblay et al., 2007b; Krebs
et al., 2007). It is assumed that similar mechanisms are operative
in vivo, basedon studies involving infusionof complex amino acid
mixtures at rates causing acute 2- to7-fold elevations in the levels
of 18 amino acids in rodents or humans, and demonstration that
such maneuvers impair skeletal muscle glucose uptake and
insulin action while increasing hepatic gluconeogenesis (Krebs
et al., 2002, 2003; Tremblay et al., 2005). However, because the
experimental design of these foregoing studies resulted in non-
physiological increases in a broad array of circulating amino
acids, the specific impact of more modest changes in BCAA
as observed in obese compared to lean humans could not be
predicted.
Therefore, a distinctive feature of the current work is that that
we have tested the effect of supplementation of HF diet with
BCAA in amounts that induce a modest rise in BCAA in rodents,
similar to that observed in human obesity, leading to the demon-
stration that such changes are sufficient to cause a reduction in
food intake while simultaneously exerting a deleterious effect
on insulin sensitivity that is independent of body weight. More-
over, our feeding study in rats was comprised of six arms (SC,
SC/BCAA, HF, HF/BCAA, HF/PF, HF/AA) that allowed us to
uniquely dissect the interactions between caloric intake and
diet composition as it relates to insulin sensitivity. Interestingly,
moderate consumption of an HF diet is required but not sufficient
to induce impairment in insulin action, as shownby theHF/PFand
SC/BCAA supplementation studies summarized in Figures S2
and S3. We show that BCAA addition to the HF diet results in
the same overaccumulation of even-chained acylcarnitine
species in skeletal muscle as caused by HF diet alone, as well
as specific accumulation of C3 and C5 acylcarnitine species,
even though much less of the HF/BCAA diet was consumed. In
contrast, BCAA supplementation of SC diet causes no accumu-
lation of acylcarnitine species. Thus, supplementation of BCAA in
an HF diet background may saturate capacity for mitochondrial322 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.fuel oxidation in muscle in the same fashion as occurs when
HF diet is fed ad-libitum (Koves et al., 2008; Muoio andNewgard,
2008), leading to accumulation of incompletely oxidized lipid-
derived metabolites.
If both the HF and HF/BCAA diets cause mitochondrial stress,
leading to insulin resistance, why does rapamycin reverse the
HF/BCAA- but not the HF-induced impairment in insulin action?
We show that phosphorylations of mTOR, S6K1, and IRS1Ser302
are all clearly and uniquely enhanced in fasted and refed HF/
BCAA-fed animals compared to the other groups (Figure 2).
Phosphorylation of IRS1Ser307 is increased in both the HF and
HF/BCAA groups in the fasted/refed state, but is specifically
and chronically elevated only in the HF/BCAA group in the fasted
state (Figure 2). Consistent with this, mTOR is also uniquely and
chronically activated by HF/BCAA feeding relative to the other
dietary groups in skeletal muscle from fasted animals, including
the HF/AA group with isonitrogenous addition of all the amino
acids (Figure 4). Finally, JNK is activated to a greater extent by
HF/BCAA feeding than by the HF or HF/AA diets (Figure 4).
Taken together, our data show that the insulin resistance
induced by HF/BCAA is mediated primarily by chronic activation
of mTOR, possibly related to the stronger constitutive activation
of JNK. This explains why the mTOR inhibitor rapamycin
reverses HF/BCAA- but not HF-induced insulin resistance. We
note that others have reported that HF diets alone can lead to
activation of mTOR, and that the effects of HF to impair insulin
sensitivity are partially reversed by knockout of S6K1 in mice
(Tremblay et al., 2007a). However, S6K1 knockout also affects
pancreatic islet function, and the potential additive effect of
BCAA supplementation of HF diet, such as occurs in human
overnutrition, was not modeled in those prior studies.
Two limitations of our study are acknowledged:
(1) Our animal studies were performed in young rats on
a rapid growth curve, whereas the human subjects were
of middle age. This may help to explain why IGF-1 levels
were lower in obese humans than in lean controls, but
not in the HF or HF/BCAA rats versus the SC group.
However, it can be argued that this makes our finding of
BCAA-driven insulin resistance in the rodent model all
the more impressive, since this occurred even in a back-
ground of normal IGF-1 levels.
(2) Humans with type 2 diabetes are not only insulin resistant
with regard to glucose metabolism, but are also refractile
to insulin regulation of protein metabolism, a condition
that is especially apparent in males (Pereira et al., 2008;
Gougeon et al., 2008). The studies described here were
performed in male rats; additional studies will be required
to determine if our findings are also relevant to females.
Our findings should be discussed in the context of three recent
studies from other laboratories. In the first, intracerebroventricu-
lar (ICV) infusion of leucine caused reduced food intake in mice
(Cota et al., 2006), although the effect of dietary BCAA supple-
mentation was not described. Other laboratories have reported
that elevations of long-chain acyl CoA levels in the hypothal-
amus, mediated by increased levels of malonyl CoA, may also
constitute an important satiety signal (He et al., 2006; Pocai
et al., 2006). Interestingly, in the current study, food intake
was reduced only by the HF/BCAA diet and not the HF/AA or
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derived satiety signals cooperate to control feeding behavior.
A second study reported that mice with knockout of the mito-
chondrial branched chain amino-transferase 2 (BCAT2) gene
exhibit severe elevations of BCAA, coupled with an increase in
food consumption and resistance to diet-induced obesity, insulin
resistance, and glucose intolerance (She et al., 2007). In addition
to the wide disparity in increases in BCAA levels in the BCAT2
knockout mice relative to our BCAA-supplemented rats (14- to
37-fold versus 0.5- to 1.5-fold, respectively), a likely explanation
for the differences in the two models is that the BCAT knockout
mice have a complete block in BCAA catabolism, whereas
BCAA catabolism is brisk in our HF/BCAA-fed rats. Leucine
catabolism is required for this amino acid to inhibit proteolysis,
but not protein synthesis (Tischler et al., 1982). The absence of
leucine-mediated suppression of proteolysis in BCAT knockout
mice contributes to high rates of protein futile cycling, which
consumes large amounts of energy. Thus, the increased food
intake and resistance to diet-induced obesity in BCAT knockout
mice is likely due to a high rate of glucose and fatty acid oxidation
required to maintain ATP stores at a level sufficient to support
protein futile cycling. In contrast, HF/BCAA-fed rats actually
have lower rates of VO2 than SC-fed rats (Figure 4), allowing
BCAA signaling pathways that lead to reduced food intake and
insulin resistance to emerge. Moreover, lean humans trend
toward higher energy expenditure when normalized for lean
body mass relative to obese subjects (Table 1), the opposite of
what was found in the BCAT2 knockout mice. For these reasons,
we believe that our feedingmodel is amore accurate reflection of
the metabolic effects of BCAA overfeeding in human obesity.
Finally, a third study by Zhang et al. reported that supplemen-
tation of leucine in the drinking water of mice had no effects in the
context of SC diet, consistent with the current findings. Contrary
to our results, however, they also showed that leucine caused an
improvement in glucose tolerance when given to HF animals
(Zhang et al., 2007). Multiple differences between the two
studies should be noted:
(1) We fed all three BCAAs as a supplement to the food,
whereas Zhang et al. gave leucine alone in the drinking
water.
(2) Leucine has no effect on consumption of HF diet in the
Zhang et al. study, whereas BCAA supplementation
reduced consumption of the HF diet in our study.
Conversely, Zhang et al. report that leucine supplementa-
tion of HF diet increases energy expenditure and slightly
lowers RQ, whereas we find that HF/BCAA feeding does
not affect VO2 or RQ relative to HF feeding.
(3) Zhang et al. did not analyze insulin signaling pathways, so
we cannot determine if mTOR, S6K, IRS1 serine phos-
phorylation or other variables were altered by leucine
supplementation. We again suggest that our study more
faithfully models human obesity, in which all three BCAAs
are elevated, and energy expenditure is not increased.
Our intent in applying a multidimensional analytical platform to
the study of human obesity was to provide a deeper under-
standing of metabolism-related variables that differ between
lean and obese individuals. The ‘‘BCAA overload’’ hypothesis
just described, derived from human data and corroborated inan animal study, suggests that in the context of a dietary pattern
that includes high fat consumption, BCAA may make an inde-




We report baseline results from 74 obese individuals and 67 lean controls.
Obese individuals enrolled from several local weight loss programs, including
the Weight Loss Maintenance Study (WLM) (n = 45), an NHLBI-sponsored
multicenter clinical trial; the Duke University bariatric surgery program (n = 13);
the Duke Diet and Fitness Center (n = 9); the low-carbohydrate, ketogenic diet
program (n = 4); and Structure House (n = 3). These programs are described in
full detail elsewhere (Haqq et al., 2005). Lean control subjects were recruited
from the surrounding community and were selected for similar age, gender,
and race distribution compared to the 45 WLM enrollees. All study measure-
ments were obtained before 10 a.m. and after an overnight fast.
Both obese and lean individuals were excluded from participation if they had
significant cardiopulmonary, renal, or liver disease or activemalignancyorwere
taking diabetes medication, systemic corticosteroids, or weight loss medica-
tion. The studies were approved by the Duke Institutional Review Board, and
all participants provided written informed consent.
Anthropometric Measurements
Weight, height, and waist circumference were measured by standard
methods.
Measures of Behavior
Dietary intake was measured by self-administered Block Food Frequency
Questionnaire (Harlan and Block, 1990). Usual physical activity was measured
by the self-administered International Physical Activity Questionnaire (Craig
et al., 2003).
Physiologic Measurements
Methods used for measurement of body composition by dual energy X-ray
absorptiometry (DEXA) and abdominal computerized tomography (CT) and of
resting energy expenditure (REE) by indirect calorimetry have been described
previously (Haqq et al., 2005).
Insulin sensitivity was measured by HOMA, using the following formula:
HOMA = (fasting insulin in mU/mL 3 fasting glucose in mM) / 22.5. Si and
AIRG were measured by IVGTT in a subset of 26 obese and 26 lean subjects,
using the insulin-modified frequently sampled IVGTT (Bergman et al., 1981;
Houmard et al., 2002).
Biochemical Measurements
Blood and urine samples were obtained after an overnight fast to measure the
analytes described below. A detailed description of blood and urine sample
preparation and coefficients of variation for these assays has been published
(Haqq et al., 2005).
Hormone Analysis
Radioimmunoassays were performed for leptin, insulin, C-peptide, glucagon,
total ghrelin, total adiponectin, peptide YY (PYY) (Linco; St. Charles, MO), and
neuropeptide Y (NPY) (Alpco; Salem, NH) in plasma samples and for pancre-
atic polypeptide (Alpco), hGH, total IGF-I, and three IGF-1 binding proteins
(IGFBP-1, IGFBP-2, IGFBP-3) (DSL; Webster, TX) in serum samples. ELISAs
were used to measure amylin and total GIP (Linco), resistin (Biovendor;
Candler, NC), and free IGF-1 (Diagnostic Systems Laboratories; Webster,
TX) in plasma samples. Total GLP-1 was measured in plasma using an assay
from Meso Scale Discovery (Gaithersburg, MD).
Conventional Metabolite Analysis
Plasma glucose, lactate, total cholesterol, HDL and low-density lipoprotein
(LDL) cholesterol, and triglycerides were measured with kits from Roche Diag-
nostics (Indianapolis, IN) and free fatty acids (total) and ketones (total and
3-hydroxybutyrate) with kits from Wako (Richmond, VA). Plasma pyruvate
was measured as described.Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc. 323
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ELISA-based assays (Biosource; Camarillo, CA) were used to measure IL-6,
IL-10, and TNF-a in serum. CRP was measured in plasma using a kit from
Roche.
Serum Acylcarnitines and Amino Acids
Acylcarnitines and amino acids were analyzed by MS/MS as described previ-
ously (An et al., 2004; Millington et al., 1990;Wu et al., 2004, Chace et al., 1995,
Ferrara et al., 2008).
Total Fatty Acids, Serum Free Fatty Acids, and Organic Acids
For determination of total fatty acids (free and esterified) in plasma samples,
fatty acid residues were aggressively transesterified to their methyl esters in
a solution of 4% v/v acetyl chloride in methanol (Lepage and Roy, 1986). To
measure nonesterified free fatty acids, separate serum samples were gently
methylated using iodomethane and purified by solid-phase extraction (Patter-
son et al., 1999). For analysis of urinary organic acids, analytes were extracted
in ethyl acetate, dried, and then converted to trimethyl silyl esters by N,O-bis
(trimethylsilyl) trifluoroacetamide, with protection of a-keto groups by oxima-
tion with ethoxyamine hydrochloride. Derivatized fatty and organic acids
were analyzed by capillary gas chromatography/mass spectrometry (GC/MS)
using a TRACE DSQ instrument (Thermo Electron Corporation; Austin, TX).
All MS analyses employed stable-isotope dilution with internal standards
from Isotec (St. Louis, MO), Cambridge Isotope Laboratories (Andover, MA),
and CDN Isotopes (Pointe-Claire, Quebec, Canada). A list of all internal stan-
dards utilized in these studies has been published (Ferrara et al., 2008).
Animals and Dietary Regimens
All procedures described in this article involving animals were approved by the
Duke University Institutional Animal Care andUse Committee. MaleWistar rats
(150–175 g, Charles River Laboratories, Durham, NC) were housed in pairs
with free access to water and feeding of the various diets shown in Table S1
for 12–16 weeks prior to biochemical and physiological analyses. We also per-
formed a ‘‘refeeding and crossfeeding’’ study, in which we fed HF/BCAA, HF,
or SC diets; fasted animals for 48 hr; and then either refed the same diets as
consumed prior to fasting or crossfed such that HF/BCAA-fed animals
received HF diet during refeeding, and HF and SC-fed animals received HF/
BCAA diet. All refeeding was performed for a period of 4 hr. We also fed rats
on HF/BCAA, HF, or SC diet; fasted for 24 hr; and injected with 0.5 mg/kg
rapamycin dissolved in ethanol or vehicle (ethanol) intraperitoneally 3 hr prior
to IPGTT. Food intake and body weights were monitored weekly.
Glucose and Insulin Tolerance Tests in Rats
For glucose tolerance tests, rats were fasted for 24 hr with free access to water
and given an i.p. injection of glucose (1 g/kg of body weight; 45% glucose).
Blood was obtained from the tail vein immediately prior to glucose injection
and every 30 min thereafter for a period of 180 min, and glucose levels were
measured with BD Logic Glucose Meter. For insulin tolerance test experi-
ments, insulin (0.75 IU/kg body weight; Humulin Regular; Eli Lilly) was injected
intraperitoneally to ad lib-fed animals. Blood samples were obtained from the
tail vein immediately prior to and every 30 min after the insulin injection for
a period of 180 min.
Indirect Calorimetry
Indirect calorimetry was performed using an eight-chamber Oxymas system
(Columbus Instruments;Columbus,OH).Rats fedon thevariousdietsdescribed
above were acclimatized to the system for 24 hr prior to measurement.
Immunoblot Analysis of Insulin Signaling Proteins
Approximately 100mg of gastrocnemiusmuscle or liver samples were homog-
enized and prepared for electrophoresis as described (An et al., 2004). Blots
were incubated overnight at 4C with anti-AKT, anti-phosphoSer473-AKT,
anti-IRS1, anti-phosphoSer302-IRS1, anti-phosphoSer307-IRS1, anti-mTOR,
anti-phosphoSer2448-mTOR, anti-S6K1, or anti-phosphoThr389-S6K1 anti-
bodies (New England Biolabs). Signals were detected using HRP-conjugated
secondary antibody and the ECL Western Blotting Analysis System (Amer-
sham Biosciences; Piscataway, NJ) and quantified with the VersaDoc Imaging
System (Bio-Rad). JNK assay was performed using a nonradioactive JNK
kinase assay kit (New England Biolabs).324 Cell Metabolism 9, 311–326, April 8, 2009 ª2009 Elsevier Inc.Statistical Analysis
For the human metabolic profiling data, results are presented as medians and
interquartile ranges, and Wilcoxon rank-sum tests were used to compare all
individual analytes in lean versus obese subjects. We also performed unsuper-
visedmultivariate analyses (PCA) using softwareprocedures inSASVersion 9.1
(SAS Institute, Inc.; Cary, NC). The level of each of the PCA-derivedmetabolite
componentswas then compared in lean versus obese subjects usingWilcoxon
rank-sum testing. In addition, correlation between PCA-derived components
and insulin resistance (as measured by HOMA) was assessed. Details of the
PCA and correlation analyses are described in the Supplemental Data. In anal-
ysis of the human profiling data, as a reasonable compromise between type I
(false positive) and type II (false negative) error, a nominal p value of 0.01 was
used for declaring a statistically significant result, with no adjustment for
multiple comparisons.
For the animal feeding studies, data are presented as averages ± SEM, and
Student’s t test was used for statistical analysis.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, one table, and four figures and can be found online at
http://www.cell.com/cellmetabolism/supplemental/S1550-4131(09)00040-0.
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